Grant: CIHR Fellowship
McMaster University
$135,000.00
Design and Implementation of a Novel High-Throughput Screening Platform to Subvert Serum Survival Strategies of Antibiotic Resistant Bacteria
EF 2016-17
Résumé
Infections cause by antibiotic resistant bacteria, or 'superbugs', have become one of the greatest threats to our healthcare system. Infections that were once considered relatively benign and easy to treat are now becoming life-threatening due to our inability to prescribe effective antibiotic therapy. As antibiotic resistance spreads, our current arsenal of antibiotics is rapidly becoming obsolete. Although the obvious solution to this problem is to develop new antibiotics, no novel class of antibiotic has been approved in the last 30 years. One approach to modern-day antibiotic discovery involves screening thousands of natural or synthetic chemicals to identify those which kill bacteria in rich growth medium. Unfortunately, antibacterial molecules identified in this way rarely translate into clinically successful antibiotics. Creative strategies to increase the likelihood of identifying new and effective antibiotics are urgently needed. To this end, this proposal aims to identify antibacterial molecules through an innovative screening approach that specifically targets bacteria that cause bloodstream infections.
Bloodstream infections (BSI) caused by antibiotic resistant bacteria are life-threatening, and in some circumstances can result in death of 50% of patients. Although blood contains antibacterial activity, pathogenic bacteria have developed strategies that allow them to survive and grow in human blood. These survival strategies are not targeted by current antibiotics, and thus represent an untapped potential for the development of novel therapies. By screening for molecules that inhibit bacterial growth in blood, but not rich growth medium, I believe that these survival strategies can be subverted. I aim to develop such a platform to screen thousands of small molecules in order to identify molecules that specifically inhibit the ability of bacteria to survive in blood. This research could pave the way for new treatments for BSI.
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
361667
Name
Weber Brent S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Design and Implementation of a Novel High-Throughput Screening Platform to Subvert Serum Survival Strategies of Antibiotic Resistant Bacteria
Programtype2
Fellowship Programs
Orgnameinp2
McMaster University
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Antibiotic Resistance; Bacterial Survival Strategies; Bloodstream Infections; High-Throughput Screening; Klebsiella Pneumoniae
Abstract
Infections cause by antibiotic resistant bacteria, or 'superbugs', have become one of the greatest threats to our healthcare system. Infections that were once considered relatively benign and easy to treat are now becoming life-threatening due to our inability to prescribe effective antibiotic therapy. As antibiotic resistance spreads, our current arsenal of antibiotics is rapidly becoming obsolete. Although the obvious solution to this problem is to develop new antibiotics, no novel class of antibiotic has been approved in the last 30 years. One approach to modern-day antibiotic discovery involves screening thousands of natural or synthetic chemicals to identify those which kill bacteria in rich growth medium. Unfortunately, antibacterial molecules identified in this way rarely translate into clinically successful antibiotics. Creative strategies to increase the likelihood of identifying new and effective antibiotics are urgently needed. To this end, this proposal aims to identify antibacterial molecules through an innovative screening approach that specifically targets bacteria that cause bloodstream infections.
Bloodstream infections (BSI) caused by antibiotic resistant bacteria are life-threatening, and in some circumstances can result in death of 50% of patients. Although blood contains antibacterial activity, pathogenic bacteria have developed strategies that allow them to survive and grow in human blood. These survival strategies are not targeted by current antibiotics, and thus represent an untapped potential for the development of novel therapies. By screening for molecules that inhibit bacterial growth in blood, but not rich growth medium, I believe that these survival strategies can be subverted. I aim to develop such a platform to screen thousands of small molecules in order to identify molecules that specifically inhibit the ability of bacteria to survive in blood. This research could pave the way for new treatments for BSI.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Weber, Brent S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~